117 related articles for article (PubMed ID: 15186837)
41. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
42. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation.
Darmoul D; Gratio V; Devaud H; Peiretti F; Laburthe M
Mol Cancer Res; 2004 Sep; 2(9):514-22. PubMed ID: 15383630
[TBL] [Abstract][Full Text] [Related]
43. Crosstalk between EGFR and extranuclear steroid receptors.
Migliaccio A; Castoria G; Di Domenico M; Ciociola A; Lombardi M; De Falco A; Nanayakkara M; Bottero D; De Stasio R; Varricchio L; Auricchio F
Ann N Y Acad Sci; 2006 Nov; 1089():194-200. PubMed ID: 17261767
[TBL] [Abstract][Full Text] [Related]
44. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones.
Traxler P; Green J; Mett H; Séquin U; Furet P
J Med Chem; 1999 Mar; 42(6):1018-26. PubMed ID: 10090785
[TBL] [Abstract][Full Text] [Related]
45. Secretin regulates paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway.
Chen MC; Solomon TE; Perez Salazar E; Kui R; Rozengurt E; Soll AH
Am J Physiol Gastrointest Liver Physiol; 2002 Oct; 283(4):G893-9. PubMed ID: 12223349
[TBL] [Abstract][Full Text] [Related]
46. Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells.
Kuribayashi A; Kataoka K; Kurabayashi T; Miura M
Endocrinology; 2004 Nov; 145(11):4976-84. PubMed ID: 15271882
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives.
Chand K; Prasad S; Tiwari RK; Shirazi AN; Kumar S; Parang K; Sharma SK
Bioorg Chem; 2014 Apr; 53():75-82. PubMed ID: 24632506
[TBL] [Abstract][Full Text] [Related]
48. Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase.
Selness SR; Devraj RV; Devadas B; Walker JK; Boehm TL; Durley RC; Shieh H; Xing L; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R; Messing D; Yang J; Mao MK; Yalamanchili G; Vonder Embse R; Hirsch J; Saabye M; Bonar S; Webb E; Anderson G; Monahan JB
Bioorg Med Chem Lett; 2011 Jul; 21(13):4066-71. PubMed ID: 21641211
[TBL] [Abstract][Full Text] [Related]
49. Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species.
Meng D; Shi X; Jiang BH; Fang J
Free Radic Biol Med; 2007 Jun; 42(11):1651-60. PubMed ID: 17462533
[TBL] [Abstract][Full Text] [Related]
50. Peroxynitrite modulates the activation of p38 and extracellular regulated kinases in PC12 cells.
Jope RS; Zhang L; Song L
Arch Biochem Biophys; 2000 Apr; 376(2):365-70. PubMed ID: 10775424
[TBL] [Abstract][Full Text] [Related]
51. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
52. Inhibitors of src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines.
Wang YD; Miller K; Boschelli DH; Ye F; Wu B; Floyd MB; Powell DW; Wissner A; Weber JM; Boschelli F
Bioorg Med Chem Lett; 2000 Nov; 10(21):2477-80. PubMed ID: 11078204
[TBL] [Abstract][Full Text] [Related]
53. X-Ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor.
Bohacek RS; Dalgarno DC; Hatada M; Jacobsen VA; Lynch BA; Macek KJ; Merry T; Metcalf CA; Narula SS; Sawyer TK; Shakespeare WC; Violette SM; Weigele M
J Med Chem; 2001 Mar; 44(5):660-3. PubMed ID: 11262076
[No Abstract] [Full Text] [Related]
54. Synthesis and docking studies of N-(5-(alkylthio)-1,3,4-oxadiazol-2-yl)methyl)benzamide analogues as potential alkaline phosphatase inhibitors.
Iqbal Z; Iqbal A; Ashraf Z; Latif M; Hassan M; Nadeem H
Drug Dev Res; 2019 Aug; 80(5):646-654. PubMed ID: 31032540
[TBL] [Abstract][Full Text] [Related]
55. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.
Choi Y; Syeda F; Walker JR; Finerty PJ; Cuerrier D; Wojciechowski A; Liu Q; Dhe-Paganon S; Gray NS
Bioorg Med Chem Lett; 2009 Aug; 19(15):4467-70. PubMed ID: 19553108
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core.
Fevig JM; Pinto DJ; Han Q; Quan ML; Pruitt JR; Jacobson IC; Galemmo RA; Wang S; Orwat MJ; Bostrom LL; Knabb RM; Wong PC; Lam PYS ; Wexler RR
Bioorg Med Chem Lett; 2001 Mar; 11(5):641-5. PubMed ID: 11266160
[TBL] [Abstract][Full Text] [Related]
57. 3-Amidinophenylalanine-based inhibitors of urokinase.
Stürzebecher J; Vieweg H; Steinmetzer T; Schweinitz A; Stubbs MT; Renatus M; Wikström P
Bioorg Med Chem Lett; 1999 Nov; 9(21):3147-52. PubMed ID: 10560742
[TBL] [Abstract][Full Text] [Related]
58. Bi-heterocyclic benzamides as alkaline phosphatase inhibitors: Mechanistic comprehensions through kinetics and computational approaches.
Abbasi MA; Nazir M; Ur-Rehman A; Siddiqui SZ; Hassan M; Raza H; Shah SAA; Shahid M; Seo SY
Arch Pharm (Weinheim); 2019 Mar; 352(3):e1800278. PubMed ID: 30624805
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of secretory phospholipase A2. 1-design, synthesis and structure-activity relationship studies starting from 4-tetradecyloxybenzamidine to obtain specific inhibitors of group II sPLA2s.
Assogba L; Ahamada-Himidi A; Habich NM; Aoun D; Boukli L; Massicot F; Mounier CM; Huet J; Lamouri A; Ombetta JE; Godfroid JJ; Dong CZ; Heymans F
Eur J Med Chem; 2005 Sep; 40(9):850-61. PubMed ID: 16084626
[TBL] [Abstract][Full Text] [Related]
60. Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors.
Jin L; Pandey P; Babine RE; Weaver DT; Abdel-Meguid SS; Strickler JE
Acta Crystallogr D Biol Crystallogr; 2005 Oct; 61(Pt 10):1418-25. PubMed ID: 16204896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
